NCT05101304Recruiting
Registre HEAR, Healthcare European Amyloidosis Registry
Source: ClinicalTrials.gov · Last updated 1 Nov 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a non-interventional, prospective, retrospective, non-comparative, multi-center study. In order not to interfere with patient management, the study is observational. Thus, no follow-up visit is imposed. The data collection will be limited to the data related to the management of the patients included throughout their follow-up. This study is intended for all patients with a confirmed or suspected diagnosis of cardiac amyloidosis. Three cohorts will be identified: the HEAR (Healthcare European Amyloidosis Registry)-Retrospective Cohort, the HEAR(Healthcare European Amyloidosis Registry)-Retrospective-Prospective Cohort and the HEAR (Healthcare European Amyloidosis Registry)-Prospective Cohort.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 5 Oct 2021
- Start date
- 29 Jun 2021
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Saving Lives Matters
- Diseases
- Amyloidosis
- NCT number
- NCT05101304
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 29 Jun 2021 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients must meet all of the following inclusion criteria to be included in the study:
- Major patient
- Protected adult patient (guardianship or curatorship)
- Prospective Cohort:
- Patients referred or who have been referred to the participating centre for suspected amyloidosis.
- Patient who signed the patient information "Prospective Cohort" note
- Retro-prospective Cohort:
- Patient already followed in the center with a confirmed diagnosis of amyloidosis Patient who signed the "retro-prospective cohort" patient information note
- Retrospective cohort:
- Deceased patients followed in the center with a confirmed diagnosis of amyloidosis
- Study participants will not be compensated for their participation
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Henri Mondor Coordinator of this site? Confirm its status | Créteil | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.